Javascript must be enabled to continue!
A distal CTCF-binding site drives MYC expression plasticity in a negative feed-forward loop
View through CrossRef
Summary
Oncogene expression heterogeneity systemically diversifies cancer cell phenotypes, enabling selection and cancer evolution. Here we document that the level of MYC expression variation is coordinated by a negative feed-forward loop involving the non-coding
CCAT1
eRNA and the
MYC
gating process. While
CCAT1
eRNA indirectly antagonizes
MYC
gating by promoting
MYC
transcriptional initiation and elongation, the MYC protein promotes gated MYC expression in a feedback loop by inhibiting both
MYC
transcription and
CCAT1
expression. This entire process is coordinated by a CTCF binding site positioned within
CCAT1
at a distal, oncogenic super-enhancer, which functions as a master switch by coordinating both
CCAT1
and gated
MYC
expression to diversify cells toward both low and high MYC levels, as determined by heterogeneity metrics. As hallmarks of this principle are frequent in breast cancer and colorectal tumors, the dynamics of this new principle may underlie transitions between therapy-resistant low-MYC, and proliferative high-MYC tumor cells.
Highlights
-
Transcriptional rate regulates
MYC
gating frequency
-
CCAT1
expression indirectly inhibits
MYC
gating by promoting
MYC
transcription
-
High MYC protein levels promote gated expression by inhibiting both
MYC
transcription and
CCAT1
expression
-
These features are controlled by a single CTCF binding in the distant super-enhancer to drive expression plasticity in colorectal cancer cells
openRxiv
Chenying Gao
Mirco Martino
Ayushi Chaurasiya
Felipe Beccaria Casagrande
Jia Pei Lim
Yuri Stephan van Ekelenburg
Wei Feng
Yan Liu
Barbara Scholz
Pragyan Mishra
Mallikarjuna Thippana
Dennis Torkornoo
Phong KC Chau
Rabia Khan
Tone Möller Tannaes
Ilias Tzelepis
Ilyas Chacoua
Natalie Geyer
Sebastian Meltzer
Anne H. Ree
Marco Gerling
Johan Hartman
Narsis Kiani
Rolf Ohlsson
Anita Göndör
Title: A distal CTCF-binding site drives MYC expression plasticity in a negative feed-forward loop
Description:
Summary
Oncogene expression heterogeneity systemically diversifies cancer cell phenotypes, enabling selection and cancer evolution.
Here we document that the level of MYC expression variation is coordinated by a negative feed-forward loop involving the non-coding
CCAT1
eRNA and the
MYC
gating process.
While
CCAT1
eRNA indirectly antagonizes
MYC
gating by promoting
MYC
transcriptional initiation and elongation, the MYC protein promotes gated MYC expression in a feedback loop by inhibiting both
MYC
transcription and
CCAT1
expression.
This entire process is coordinated by a CTCF binding site positioned within
CCAT1
at a distal, oncogenic super-enhancer, which functions as a master switch by coordinating both
CCAT1
and gated
MYC
expression to diversify cells toward both low and high MYC levels, as determined by heterogeneity metrics.
As hallmarks of this principle are frequent in breast cancer and colorectal tumors, the dynamics of this new principle may underlie transitions between therapy-resistant low-MYC, and proliferative high-MYC tumor cells.
Highlights
-
Transcriptional rate regulates
MYC
gating frequency
-
CCAT1
expression indirectly inhibits
MYC
gating by promoting
MYC
transcription
-
High MYC protein levels promote gated expression by inhibiting both
MYC
transcription and
CCAT1
expression
-
These features are controlled by a single CTCF binding in the distant super-enhancer to drive expression plasticity in colorectal cancer cells.
Related Results
High Order Chromatin Structure Regulates Gene Expression in Hematopoietic Stem Cell Self-Renewal and Erythroid Differentiation
High Order Chromatin Structure Regulates Gene Expression in Hematopoietic Stem Cell Self-Renewal and Erythroid Differentiation
Abstract
High order chromatin structure is implicated in multiple developmental processes and disease. However, a global picture of chromosomal looping interaction a...
Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract
Small cell lung cancer and large cell neuroendocrine carcinoma are classified as high-grade neuroendocrine tumors of the lung, representing extremely agg...
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients. This st...
Improving immunotherapy in high-grade B-cell lymphoma
Improving immunotherapy in high-grade B-cell lymphoma
MYC is a transcription factor that upon deregulation acts as an oncogene. Cancer patients with MYC overexpression face significant worse outcomes to treatment with (immuno)chemothe...
Flow Cytometry and Cytogenetics of Fine Needle Aspiration Biopsy Samples Is a Reliable Method for Diagnosing Burkitt Lymphoma. Evaluation of 78 Cases from a Single-Institution
Flow Cytometry and Cytogenetics of Fine Needle Aspiration Biopsy Samples Is a Reliable Method for Diagnosing Burkitt Lymphoma. Evaluation of 78 Cases from a Single-Institution
Abstract
Background: The diagnosis of Burkitt lymphoma (BL) is usually based on histopathology (HP), immunohistochemistry (IHC), fluorescence in situ hybridization (...
Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia
Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia
Abstract
Background and significance. Stemness in acute myeloid leukemia (AML) is determined by a clonal hierarchy with ...
Investigation of the interaction between CTCF and DNA using AFM imaging
Investigation of the interaction between CTCF and DNA using AFM imaging
CCCTC binding factor (CTCF) is a highly conserved zinc finger protein found in all eukaryotes. Originally it was studied as a traditional transcription factor. Later on, the CTCF b...
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract
Medulloblastoma is the most common malignant brain tumor in children. Currently, treatment consists of surgical resection, chemotherapy, and whole brain and...

